Amendment: SEC Form SC 13G/A filed by Ocular Therapeutix Inc.
$OCUL
Biotechnology: Pharmaceutical Preparations
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/15/2025 | $21.00 | Buy | Chardan Capital Markets |
| 4/8/2025 | Outperform | William Blair | |
| 3/18/2025 | $17.00 | Outperform | RBC Capital Mkts |
| 3/11/2025 | $15.00 | Buy | Needham |
| 10/16/2024 | Sector Outperform | Scotiabank | |
| 6/20/2024 | $7.00 → $11.00 | Hold → Buy | TD Cowen |
| 5/31/2024 | $15.00 | Overweight | Piper Sandler |
| 2/9/2024 | $15.00 | Buy | BofA Securities |
4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)
4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)
4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)
BEDFORD, Mass., June 04, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation at Clinical Trials at the Summit 2026, taking place on June 12-13, 2026, in Las Vegas, Nevada. Clinical Trials at the Summit (CTS) 2026 Presentation Details: Fireside Chat with Wiley Chambers, MDFireside Date/Time: Friday, June 12, 2026, 8:05 – 8:30 PM PTModerators: Jeffrey S. Heier, MD, Chief Scientific Officer; Peter K. Kaiser, MD, Chief Development Officer Presentation Title: OTX-TKI: Overview of ScienceSession: Clinical Trials Addressing nAMD, DME, and DRPresentation D
In addition to Ocular leadership, event to feature prominent retinal disease experts Dr. Arshad M. Khanani, MD, MA, FASRS; Dr. Lejla Vajzovic, MD, FASRS; and Dr. Darius M. Moshfeghi, MD Company to highlight AXPAXLI™ wet AMD NDA submission plan, updates on SOL-R, SOL-X, and registrational diabetic retinopathy program, and an overview of the planned commercialization approach for AXPAXLI, if approved The live event will take place in New York City on June 17, 2026, starting at 2:00 PM ET BEDFORD, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), an integrated biopharmaceutical company committed to redefining the retina experience, will host
BEDFORD, Mass., May 08, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular" or the "Company")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to twelve newly hired non-executive employees. The awards were made as an inducement material to each recipient's acceptance of employment with Ocular under Ocular's 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement equity awards were granted effective as of May 4, 2026, and consist of non-statutory stock option awards to purchase up to an aggregate of 127,650 shares of Ocular's comm
Chardan Capital Markets initiated coverage of Ocular Therapeutix with a rating of Buy and set a new price target of $21.00
William Blair initiated coverage of Ocular Therapeutix with a rating of Outperform
RBC Capital Mkts initiated coverage of Ocular Therapeutix with a rating of Outperform and set a new price target of $17.00
10-Q - OCULAR THERAPEUTIX, INC (0001393434) (Filer)
8-K - OCULAR THERAPEUTIX, INC (0001393434) (Filer)
DEFA14A - OCULAR THERAPEUTIX, INC (0001393434) (Filer)
4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)
4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)
4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)
Accomplished global commercial leader with deep expertise in retina drug launches Primary architect for the industry-defining launch of EYLEA® while at Regeneron Most recently served as Chief Marketing Officer, Global Ophthalmology at Merck BEDFORD, Mass., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that David W. Robinson has agreed to join the Company as Global Chief Commercial Officer. The appointment of Mr. Robinson, a proven commercial leader with a history of launching category-defining therapies, strategically positions Ocular for success
Company to highlight corporate strategy, clinical data, and development plans for AXPAXLI™ in wet AMD and NPDR Event to feature prominent retinal disease experts Baruch D. Kuppermann, MD, PhD (University of California, Irvine) and Dilsher S. Dhoot, MD (California Retina Consultants) In-person event with virtual access to take place on June 13, 2024, at 2:00 PM ET BEDFORD, Mass., June 05, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular", the "Company"))), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD
Recent Leadership Appointments Put Ocular on Track to Become a Leader in Retinal Care Site Activation and Patient Enrollment for AXPAXLI™ SOL-1 Phase 3 wet AMD Trial Progressing with First Subjects Randomized in April 2024 Cash Expected to Support Operations Into 2028, Based on $482.9M March 31, 2024, Cash Balance June 13, 2024, Investor Day to Outline Updated Corporate Strategy BEDFORD, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular", the "Company"))), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degenerati
Enrollment underway in SOL-X long-term extension trial in wet AMD for subjects completing two-year follow-up in SOL-1 or SOL-R Announced positive Phase 3 SOL-1 results in February 2026, first ever successful wet AMD superiority trial comparing a novel investigative agent to an approved anti-VEGF SOL-1 Week 52 data presentations held at Macula Society and VBS meetings reinforce AXPAXLI's unmatched durability and sustained disease control data in wet AMD Commercial preparedness plans accelerated as Ocular intends to submit AXPAXLI NDA based on SOL-1 Week 52 data, subject to ongoing formal discussions with the U.S. FDA SOL-R Phase 3 non-inferiority trial in wet AMD on track for topline read
BEDFORD, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it plans to host a conference call and webcast on Tuesday, May 5, 2026 at 8:00 AM ET to discuss recent business progress and financial results for the first quarter ended March 31, 2026. Conference Call and Webcast Information: Date: Tuesday, May 5, 2026 at 8:00 AM ETParticipant Dial-In (U.S.): 1-800-343-4136Participant Dial-In (International): 1-203-518-9843Conference ID: OCULAR (required for entry)Webcast Access: Please click here The live and archived webcast can also be access
Ocular to present detailed SOL-1 data at the 49th Macula Society Annual Meeting on Friday, February 27, 2026, starting at 1:00 PM PT (4:00 PM ET) Company to host an investor webcast on Monday, March 2, 2026, at 7:30 AM ET to discuss the Macula Society presentations BEDFORD, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that the Company will present detailed results from the SOL-1 Phase 3 superiority clinical trial of AXPAXLI™ (also known as OTX-TKI), for the treatment of wet age-related macular degeneration (wet AMD), at the 49th Macula Soc
SC 13G/A - OCULAR THERAPEUTIX, INC (0001393434) (Subject)
SC 13G - OCULAR THERAPEUTIX, INC (0001393434) (Subject)
SC 13G/A - OCULAR THERAPEUTIX, INC (0001393434) (Subject)